Psychedelic Therapy for Addiction
Substance use disorders — including alcohol, opioid, tobacco, and cocaine addiction — are a major research focus for psychedelic medicine. Ibogaine shows dramatic results for opioid use disorder, with Texas allocating $50M for university research programs. Psilocybin trials for alcohol use disorder at Johns Hopkins and NYU have produced significant abstinence rates, and ketamine is being studied for multiple addiction types.
What makes psychedelics promising for addiction is their ability to disrupt habitual patterns, reduce craving-related brain activity, and facilitate the psychological insight needed for lasting behavioral change — often in a single or small number of sessions rather than ongoing medication.
Clinical Trials
No trials found
There are currently no clinical trials for Addiction in our database.